Comparison of clinicopathological features among progressor (N=75) and non-progressor patients (N=148)
| Clinical parameters | BE non-progressor | BE progressor | OR (95% CI) | P value |
| Gender | 0.001 | |||
| Male | 93 (63%) | 63 (84%) | 3.1 | |
| Female | 55 (37%) | 12 (16%) | (1.5 to 6.3) | |
| Mean age in years at diagnosis of BE | 56.3 ± 10.9, 57 | 62.7 ± 11.8, 61.2 | <0.001 | |
| Mean±SD, median, range | 24–81 | 29.5–87.1 | ||
| Age | 0.008 | |||
| ≤55 years | 62 (42%) | 18 (24%) | 2.3 | |
| >55 years | 86 (58%) | 57 (76%) | (1.2 to 4.3) | |
| BMI (N=231) | 28.3 ± 5.3, 28.0, 15.5–49.6 | 29.5 ± 6.2, 28.7, 17–48.2 | 0.222 | |
| Obesity (BMI >30) (n=182) | ||||
| Yes | 35 (27%) | 19 (37%) | 0.6 | 0.162 |
| No | 96 (73%) | 32 (63%) | (0.3 to 1.2) | |
| History of smoking (n=180) | 0.118 | |||
| Smokers | 66 (57%) | 44 (69%) | 0.6 | |
| Non-smokers | 50 (43%) | 20 (31%) | (0.3 to 1.1) | |
| History of alcohol intake (N=168) | ||||
| Yes | 66 (59%) | 26 (46%) | 1.7 | 0.125 |
| No | 46 (41%) | 30 (54%) | (0.9 to 3.2) | |
| Mean length of BE in cm (n=211) mean±SD, median, range | 2.6 ± 2.5, 1.0, 1.0–15.0 | 5.0 ± 3.4, 4, 1–15 | <0.001 | |
| Endoscopic type of BE | <0.001 | |||
| Long BE (≥3 cm) | 47 (33%) | 48 (71%) | 4.9 | |
| Short BE (<3 cm) | 96 (67%) | 20 (29%) | (2.6 to 9.2) | |
| Highest grade of neoplasia | – | HGD=36 (48%) EAC 39 (52%) | – | |
| Mean follow-up in years±SD, median | 10.3±5.1, 11* | 5.4±5.1, 3† | <0.001 |
*Time difference between the date of biopsy on which the diagnosis of BE was made and the date of the last available oesophageal biopsy with BE.
†Time difference between the date of biopsy on which the diagnosis of BE was made and that biopsy on which detected progression to HGD/EAC.
BE, Barrett’s oesophagus; BMI, body mass index; EAC, oesophageal adenocarcinoma,; HGD, high-grade dysplasia.